{"id":"placebo-etoposide-and-cisplatin","safety":{"commonSideEffects":[{"rate":"30-90%","effect":"Nausea"},{"rate":"20-80%","effect":"Vomiting"},{"rate":"20-60%","effect":"Neutropenia"},{"rate":"10-50%","effect":"Anemia"},{"rate":"10-40%","effect":"Thrombocytopenia"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-20%","effect":"Anorexia"},{"rate":"5-15%","effect":"Weight loss"},{"rate":"5-10%","effect":"Hair loss"}]},"_chembl":{"chemblId":"CHEMBL2447941","moleculeType":"Small molecule","molecularWeight":"629.38"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Etoposide works by inhibiting the enzyme topoisomerase II, which is involved in DNA replication and repair. This leads to DNA damage and ultimately cell death. Cisplatin, on the other hand, forms platinum-DNA adducts, which interfere with DNA replication and transcription, causing cell death.","oneSentence":"Etoposide is a topoisomerase II inhibitor, and cisplatin is a platinum-based DNA crosslinking agent.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:26:54.617Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Small cell lung cancer, Non-small cell lung cancer, Testicular cancer, Ovarian cancer"}]},"trialDetails":[{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT05353257","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2022-05-17","conditions":"Limited-Stage Small Cell Lung Cancer","enrollment":511},{"nctId":"NCT03519971","phase":"PHASE3","title":"Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-03-29","conditions":"Non-Small Cell Lung Cancer","enrollment":328},{"nctId":"NCT04380636","phase":"PHASE3","title":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-06","conditions":"Lung Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":870},{"nctId":"NCT05224141","phase":"PHASE3","title":"Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-03-24","conditions":"Small Cell Lung Carcinoma","enrollment":460},{"nctId":"NCT04624204","phase":"PHASE3","title":"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-08","conditions":"Small Cell Lung Cancer","enrollment":672},{"nctId":"NCT06851819","phase":"PHASE2","title":"Tislelizumab in Combination with Chemotherapy ± Radiotherapy for Extensive-Stage Oligometastatic Small Cell Lung Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-03-01","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":64},{"nctId":"NCT04005716","phase":"PHASE3","title":"Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-07-22","conditions":"Small Cell Lung Cancer","enrollment":457},{"nctId":"NCT00791154","phase":"PHASE1, PHASE2","title":"QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer","status":"TERMINATED","sponsor":"NantCell, Inc.","startDate":"2008-12-02","conditions":"Lung Cancer, Small Cell Lung Cancer, Solid Tumors","enrollment":213},{"nctId":"NCT05913427","phase":"PHASE2","title":"Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)","status":"RECRUITING","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2022-06-08","conditions":"Adrenocortical Carcinoma","enrollment":80},{"nctId":"NCT06372626","phase":"PHASE1, PHASE2","title":"Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.","status":"RECRUITING","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2024-05-30","conditions":"Neuroendocrine Carcinoma","enrollment":93},{"nctId":"NCT03840902","phase":"PHASE2","title":"M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2019-04-16","conditions":"Non-small Cell Lung Cancer","enrollment":153},{"nctId":"NCT01642251","phase":"PHASE1, PHASE2","title":"Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-09-28","conditions":"Extensive Stage Small Cell Lung Carcinoma, Large Cell Lung Carcinoma, Neuroendocrine Carcinoma","enrollment":156},{"nctId":"NCT00453154","phase":"PHASE1, PHASE2","title":"Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-03-15","conditions":"Extensive Stage Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma","enrollment":156},{"nctId":"NCT03066778","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-05-02","conditions":"Small Cell Lung Cancer (SCLC)","enrollment":453},{"nctId":"NCT02768558","phase":"PHASE3","title":"Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC","status":"TERMINATED","sponsor":"RTOG Foundation, Inc.","startDate":"2016-10-17","conditions":"Non-Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT03116971","phase":"PHASE1","title":"Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2017-05-25","conditions":"Small Cell Lung Cancer","enrollment":2},{"nctId":"NCT01859741","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy","status":"TERMINATED","sponsor":"OncoMed Pharmaceuticals, Inc.","startDate":"2012-01-07","conditions":"Stage IV Small Cell Lung Cancer","enrollment":172},{"nctId":"NCT03745222","phase":"PHASE3","title":"A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Celgene","startDate":"2019-05-22","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":1},{"nctId":"NCT01450761","phase":"PHASE3","title":"Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12-13","conditions":"Small Cell Lung Carcinoma","enrollment":1351},{"nctId":"NCT04203511","phase":"PHASE3","title":"INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)","status":"WITHDRAWN","sponsor":"Incyte Corporation","startDate":"2020-07-31","conditions":"Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT00613626","phase":"PHASE2","title":"Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hoosier Cancer Research Network","startDate":"2008-01","conditions":"Small Cell Lung Cancer","enrollment":74},{"nctId":"NCT02161419","phase":"PHASE2","title":"RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Bayer","startDate":"2014-07-30","conditions":"Small Cell Lung Carcinoma","enrollment":142},{"nctId":"NCT02875457","phase":"PHASE3","title":"Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin","status":"UNKNOWN","sponsor":"Third Military Medical University","startDate":"2016-09","conditions":"Small Cell Lung Cancer","enrollment":100},{"nctId":"NCT00433498","phase":"PHASE3","title":"Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer","status":"COMPLETED","sponsor":"University College, London","startDate":"2007-01","conditions":"Lung Cancer","enrollment":846},{"nctId":"NCT00020709","phase":"PHASE3","title":"Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-06","conditions":"Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer","enrollment":840},{"nctId":"NCT00403403","phase":"PHASE2","title":"A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-03","conditions":"Small Cell Lung Cancer","enrollment":102},{"nctId":"NCT00119613","phase":"PHASE3","title":"A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-12","conditions":"Small Cell Lung Cancer","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"placebo;etoposide and cisplatin","genericName":"placebo;etoposide and cisplatin","companyName":"Third Military Medical University","companyId":"third-military-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etoposide is a topoisomerase II inhibitor, and cisplatin is a platinum-based DNA crosslinking agent. Used for Small cell lung cancer, Non-small cell lung cancer, Testicular cancer, Ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}